Literature DB >> 24012580

Adverse health outcomes associated with surgical management of the small renal mass.

Brian Shuch1, Janet M Hanley2, Julie C Lai2, Srinivas Vourganti3, Claude M Setodji2, Andrew W Dick2, Wong-Ho Chow4, Chris S Saigal5.   

Abstract

PURPOSE: Partial and radical nephrectomy are treatments for the small renal mass. Partial nephrectomy is considered the gold standard as it may protect against renal dysfunction compared to radical nephrectomy. However, both treatments may cause adverse health outcomes.
MATERIALS AND METHODS: A matched cohort study was performed using the SEER (Surveillance, Epidemiology and End Results)-Medicare data set. Individuals treated with partial or radical nephrectomy for 4 cm or smaller nonmetastatic renal cell carcinoma were compared to 2 control groups (nonmuscle invasive bladder cancer and noncancer). A greedy algorithm matched surgical groups to controls. Medicare claims were examined for renal, cardiovascular and secondary cancer events.
RESULTS: Patients who underwent partial nephrectomy (1,471) and radical nephrectomy (4,299) were matched to controls. The time to event model demonstrated an increased risk of renal events for both treatments. Compared to the bladder cancer control and noncancer control groups, radical nephrectomy hazard ratios for renal events were 2.415 (p <0.0001) and 6.211 (p <0.0001), respectively, while partial nephrectomy hazard ratios were 1.513 (p <0.0001) and 4.926 (p <0.0001), respectively. Secondary cancers were increased for partial nephrectomy and radical nephrectomy compared to both control groups (p <0.0001). Cardiovascular events were increased for both treatments compared to noncancer controls (p <0.0001), but not compared to bladder cancer controls.
CONCLUSIONS: Partial nephrectomy and radical nephrectomy may lead to adverse health outcomes. Compared to controls, partial nephrectomy and radical nephrectomy are associated with worsened renal outcomes. The increase in secondary cancers and cardiovascular events with both treatments is notable, and requires further investigation. Further research should investigate if active surveillance of the appropriately selected small renal mass limits adverse health outcomes.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AS; BCC; CCI; CKD; CSS; Charlson comorbidity index; ESRD; HTN; NCC; PN; RCC; RN; SRM; active surveillance; bladder cancer control; cancer specific survival; chronic kidney disease; end stage renal disease; hypertension; kidney neoplasms; nephrectomy; noncancer control; partial nephrectomy; radical nephrectomy; renal cell carcinoma; small renal mass; watchful waiting

Mesh:

Year:  2013        PMID: 24012580     DOI: 10.1016/j.juro.2013.08.074

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  End-Stage Kidney Disease following Surgical Management of Kidney Cancer.

Authors:  Robert J Ellis; Daniel P Edey; Sharon J Del Vecchio; Megan McStea; Scott B Campbell; Carmel M Hawley; David W Johnson; Christudas Morais; Susan J Jordan; Ross S Francis; Simon T Wood; Glenda C Gobe
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-28       Impact factor: 8.237

2.  [Watchful waiting and active surveillance of small renal masses].

Authors:  R Mager; S Frees; A Haferkamp
Journal:  Urologe A       Date:  2018-03       Impact factor: 0.639

3.  Radical versus partial nephrectomy, chronic kidney disease progression and mortality in US veterans.

Authors:  Elani Streja; Kamyar Kalantar-Zadeh; Miklos Z Molnar; Jaime Landman; Onyebuchi A Arah; Csaba P Kovesdy
Journal:  Nephrol Dial Transplant       Date:  2018-01-01       Impact factor: 5.992

Review 4.  Renal Cancer in the Elderly.

Authors:  Tania González León; Maricela Morera Pérez
Journal:  Curr Urol Rep       Date:  2016-01       Impact factor: 3.092

5.  Cause-Specific Mortality Among Survivors From T1N0M0 Renal Cell Carcinoma: A Registry-Based Cohort Study.

Authors:  Zhixian Wang; Jing Wang; Yunpeng Zhu; Chang Liu; Xing Li; Xiaoyong Zeng
Journal:  Front Oncol       Date:  2021-03-10       Impact factor: 6.244

6.  Genomic Heterogeneity and the Small Renal Mass.

Authors:  Daiki Ueno; Zuoquan Xie; Marta Boeke; Jamil Syed; Kevin A Nguyen; Patrick McGillivray; Adebowale Adeniran; Peter Humphrey; Garrett M Dancik; Yuval Kluger; Zongzhi Liu; Harriet Kluger; Brian Shuch
Journal:  Clin Cancer Res       Date:  2018-05-14       Impact factor: 12.531

7.  Tumor size, stage and grade alterations of urinary peptidome in RCC.

Authors:  Clizia Chinello; Marta Cazzaniga; Gabriele De Sio; Andrew James Smith; Angelica Grasso; Bernardo Rocco; Stefano Signorini; Marco Grasso; Silvano Bosari; Italo Zoppis; Giancarlo Mauri; Fulvio Magni
Journal:  J Transl Med       Date:  2015-10-20       Impact factor: 5.531

8.  Growth kinetics of small renal mass: Initial analysis of active surveillance registry.

Authors:  Sung-Woo Park; Seung Soo Lee; Dong Hoon Lee; Jong Kil Nam; Moon Kee Chung
Journal:  Investig Clin Urol       Date:  2017-10-23

Review 9.  Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer.

Authors:  Francesco Trevisani; Matteo Floris; Roberto Minnei; Alessandra Cinque
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

Review 10.  Surveillance for low-risk kidney cancer: a narrative review of contemporary worldwide practices.

Authors:  Helen Wei Cui; Mark Edward Sullivan
Journal:  Transl Androl Urol       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.